| The SEZ in Indore, an export-oriented facility, will manufacture finished drugs. The first phase will come up in 18-20 months. |
| "The land has been allotted to us and the developmental activities are being carried out. The SEZ is to tap the potential in international markets, especially in the regulated markets. Facilities at the Pithambur SEZ will match all international regulatory norms," said Dr Prakash Mody, chairman and managing director. |
| Sources said Unichem planned to invest about Rs100-120 crore in the SEZ, in two phases. Further, the company will set up a new plant at Baddi, where it has already set up two units to cater to the domestic market. Unichem is also expanding the manufacturing facilities at Aurangabad in Maharashtra. The two facilities will cost about Rs 50 crore. Unichem, which achieved a Rs 562 crore turnover in 2006-07, is likely to touch a turnover of Rs 800 crore in the current financial year. |
| The company was scouting for alliances with global pharmaceutical majors to strengthen its presence in the US and the European regulated markets, Mody had said at the annual general meeting (AGM) of Unichem in Mumbai this week. |
| At present, the company has supply and marketing alliances with Lannett Company and Pliva, which was taken over by Barr. So far, Unichem has filed five abbreviated new drug applications (ANDA) and the applications for marketing generic drugs in the US with the US Food and Drug Administration (FDA). It plans to file another eight to ten ANDAs during the current financial year. |
| Unichem has a wide chronic care portfolio, especially in the cardiovascular and diabetology therapeutic segments. The company is concentrating on developing new drug delivery systems and to enhance quality and strengths of existing therapeutic drugs. A new marketing division, Unikare, was floated recently to tap the potential in the dermatology segment of the domestic market, Mody said. |
Top Section
Explore Business Standard